drugset
drugset / Trial / NCT05123209

Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors

NCT05123209 ↗

Phase 1 Unknown 12 enrolled Beijing Immunochina Medical Science & Technology Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a open-label, single center, cohort study to determine the efficacy and safety of IM83 CAR-T cells in patients with advanced Liver Tumors.

Timeline

Start
2021-08-24
Primary completion
2023-08-30
Completion
2023-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject IM83 CAR-T Cells Cell therapy 3e+09 cells —

Indications

liver cancer